Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Drug releasing stents].

Ernesto Ban Hayashi1

  • 1Departamento de Hemodinámica, Instituto Nacional de Cardiología Ignacio Chávez INCICH, Juan Badiano No. 1, Col. Sección, XVI, Tlalpan, 14080 México D.F.

Archivos De Cardiologia De Mexico
|September 12, 2003
PubMed
Summary

Drug eluting stents significantly reduce restenosis and major adverse cardiac events (MACE) in coronary heart disease treatment. Survival rates and revascularization needs are comparable to historical surgical outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial.

Circulation·2005
Same author

A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.

The New England journal of medicine·2002
Same author

[Septal ablation in the treatment of hypertrophic myocardiopathy].

Archivos de cardiologia de Mexico·2002
See all related articles

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Biomedical Engineering

Context:

  • Coronary heart disease management.
  • Advancements in interventional cardiology.
  • Drug eluting stent (DES) technology.

Purpose:

  • To evaluate the clinical impact of drug eluting stents.
  • To compare DES outcomes with historical surgical data.
  • To assess restenosis, late loss, and Major Adverse Cardiac Events (MACE).

Summary:

  • Drug eluting stents have become a standard treatment for coronary heart disease.
  • Implementation of DES has led to significant reductions in restenosis and late loss.
  • This translates to fewer MACE, primarily by reducing the need for re-intervention.

Impact:

  • DES offer comparable survival-free and revascularization-free rates to historical surgical interventions.
  • Improved patient outcomes and reduced healthcare utilization.
  • Established DES as a mainstream, effective therapy for coronary artery disease.

Related Experiment Videos